Lumida
/RGNX
⌘K
Regenxbio Inc

Regenxbio Inc

RGNX
$9.89USD-11.70%-1.31 today

MARKET CAP

511.3M

P/E (TTM)

FWD P/E

DAY RANGE

$8 – $10

52W RANGE

$5
$16

AI Summary

Stalk
StalkMedium

RGNX remains in a Stage 2 advance with clear higher highs and higher lows supported by rising short-term EMAs and expanding volume. The active Momentum Breakout signals new demand overwhelming prior supply at resistance. Price is extended above EMAs and in overbought territory, so short-term timing is unclear—execution should be deferred to pullbacks into rising EMA support or the breakout zone. Medium-term bias stays bullish while the long-term trend remains bearish.

  • $100M AbbVie milestone from dosing first patient in Phase IIb/III trial.
  • RGX202 hit primary endpoints in DMD trial with robust safety.
  • Negative earnings yield and weak profitability hinder financial sustainability.
Full analysis →
Insider Trades41 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jul 2, 2026SellRGNXSteve PakolaChief Medical Officer4,322$10.75$511.3M-38.91%+81.30%$46.5K+0.00%10b5-1Stalk
Jun 29, 2026SellRGNXSteve PakolaChief Medical Officer93,058$10.50$511.3M-38.91%+81.30%$977.4K-2.57%10b5-1Stalk
May 11, 2026SellRGNXSteve PakolaChief Medical Officer15,309$11.02$511.3M-38.91%+81.30%$168.7K-6.17%10b5-1Stalk
Mar 10, 2026SellRGNXSteve PakolaChief Medical Officer5,124$10.35$511.3M-38.91%+81.30%$53.0K-2.02%10b5-1Stalk
Feb 1, 2026SellRGNXPatrick J. ChristmasChief Strategy & Legal Officer4,700$11.16$511.3M-38.91%+81.30%$52.5K-2.18%Stalk
Feb 1, 2026SellRGNXSteve PakolaChief Medical Officer5,267$11.16$511.3M-38.91%+81.30%$58.8K-2.04%Stalk
Jan 2, 2026SellRGNXCraig MalzahnChief Technology Officer1,238$14.40$511.3M-38.91%+81.30%$17.8K-7.04%Stalk
Jan 2, 2026SellRGNXPatrick J. ChristmasChief Strategy & Legal Officer9,793$14.40$511.3M-38.91%+81.30%$141.0K-6.47%Stalk
Jan 2, 2026SellRGNXSteve PakolaChief Medical Officer18,247$14.40$511.3M-38.91%+81.30%$262.8K-8.66%Stalk
Jan 2, 2026SellRGNXCurran SimpsonChief Executive Officer18,559$14.40$511.3M-38.91%+81.30%$267.2K-8.59%Stalk
Dec 31, 2025SellRGNXCurran SimpsonChief Executive Officer9,222$12.00$511.3M-38.91%+81.30%$110.7K-0.43%Stalk
Oct 9, 2025SellRGNXCurran SimpsonChief Executive Officer20,811$12.62$511.3M-38.91%+81.30%$262.6K-8.78%10b5-1Stalk
Sep 29, 2025SellRGNXCurran SimpsonChief Executive Officer7,624$10.03$511.3M-38.91%+81.30%$76.5K-3.12%10b5-1Stalk
Sep 10, 2025SellRGNXCurran SimpsonChief Executive Officer7,734$10.02$511.3M-38.91%+81.30%$77.5K-3.07%10b5-1Stalk
Sep 1, 2025SellRGNXCraig MalzahnChief Technology Officer234$8.93$511.3M-38.91%+81.30%$2.1K-1.31%Stalk
Sep 1, 2025SellRGNXMitchell ChanChief Financial Officer4,901$8.93$511.3M-38.91%+81.30%$43.8K-8.33%Stalk
Aug 1, 2025SellRGNXPatrick J. ChristmasChief Strategy & Legal Officer4,699$8.19$511.3M-38.91%+81.30%$38.5K-3.01%Stalk
Jul 1, 2025SellRGNXCurran SimpsonChief Executive Officer4,701$8.23$511.3M-38.91%+81.30%$38.7K-1.83%Stalk
Feb 1, 2025SellRGNXPatrick J. ChristmasChief Legal Officer4,700$8.07$511.3M-38.91%+81.30%$37.9K-2.92%Stalk
Feb 1, 2025SellRGNXSteve PakolaChief Medical Officer5,263$8.07$511.3M-38.91%+81.30%$42.5K-2.44%Stalk
Feb 1, 2025SellRGNXOlivier DanosChief Scientific Officer5,452$8.07$511.3M-38.91%+81.30%$44.0K-2.35%Stalk
Jan 2, 2025SellRGNXPatrick J. ChristmasChief Legal Officer11,395$7.73$511.3M-38.91%+81.30%$88.1K-2.88%Stalk
Jan 2, 2025SellRGNXCurran SimpsonChief Executive Officer11,917$7.73$511.3M-38.91%+81.30%$92.1K-1.84%Stalk
Jan 2, 2025SellRGNXOlivier DanosChief Scientific Officer12,630$7.73$511.3M-38.91%+81.30%$97.6K-4.50%Stalk
Jan 2, 2025SellRGNXSteve PakolaChief Medical Officer13,891$7.73$511.3M-38.91%+81.30%$107.4K-5.16%Stalk
Aug 1, 2024SellRGNXCurran SimpsonChief Executive Officer100$15.00$511.3M-38.91%+81.30%$1.5K-0.06%10b5-1Stalk
Jul 29, 2024SellRGNXCurran SimpsonChief Executive Officer9,648$15.04$511.3M-38.91%+81.30%$145.1K-5.37%10b5-1Stalk
Jun 28, 2024BuyRGNXOlivier DanosChief Scientific Officer1,363$9.95$511.3M-38.91%+81.30%$13.6K+1.09%Stalk
May 14, 2024SellRGNXKenneth T. MillsPresident and CEO30,000$9.79$511.3M-38.91%+81.30%$293.6K+0.00%10b5-1Stalk
Apr 15, 2024SellRGNXKenneth T. MillsPresident and CEO30,000$10.98$511.3M-38.91%+81.30%$329.3K+0.00%10b5-1Stalk
Mar 19, 2024BuyRGNXVittal VasistaChief Financial Officer20,041$3.76$511.3M-38.91%+81.30%$75.4K+8.85%Stalk
Mar 14, 2024SellRGNXKenneth T. MillsPresident and CEO30,000$12.81$511.3M-38.91%+81.30%$384.3K+0.00%10b5-1Stalk
Mar 5, 2024SellRGNXSteve PakolaChief Medical Officer25,756$25.31$511.3M-38.91%+81.30%$651.8K+0.00%10b5-1Stalk
Feb 14, 2024SellRGNXKenneth T. MillsPresident and CEO30,000$10.26$511.3M-38.91%+81.30%$307.7K+0.00%10b5-1Stalk
Jan 16, 2024SellRGNXKenneth T. MillsPresident and CEO90,000$9.47$511.3M-38.91%+81.30%$852.2K+0.00%10b5-1Stalk
Jan 2, 2024SellRGNXVittal VasistaChief Financial Officer4,534$17.95$511.3M-38.91%+81.30%$81.4K-1.56%Stalk
Jan 2, 2024SellRGNXPatrick J. ChristmasChief Legal Officer7,893$17.95$511.3M-38.91%+81.30%$141.7K-5.48%Stalk
Jan 2, 2024SellRGNXCurran SimpsonChief Oper. & Tech. Officer8,120$17.95$511.3M-38.91%+81.30%$145.8K-5.27%Stalk
Jan 2, 2024SellRGNXKenneth T. MillsPresident and CEO11,357$17.95$511.3M-38.91%+81.30%$203.9K-1.72%Stalk
Jan 2, 2024SellRGNXSteve PakolaChief Medical Officer27,622$17.60$511.3M-38.91%+81.30%$486.2K-9.93%10b5-1Stalk
Dec 19, 2023SellRGNXKenneth T. MillsPresident and CEO90,000$11.67$511.3M-38.91%+81.30%$1.1M+0.00%10b5-1Stalk